tirzepatide muscle and composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial muscle pain after tirzepatide injection

The prevalence of seizure clusters varies among populations with epilepsy, with an estimated 3.0% of people from a large, population-based sample [7, 8] but was notably higher among patients with drug-resistant epilepsy at an epilepsy center [7, 9]

Details of diagnosis codes for study outcomes are in eTable 3 in Supplement 1

Imperato, DO, MPH (@nickimperato14, Emergency Medicine Resident, Rutgers New Jersey Medical School)

A daily dose of oral semaglutide did not delay progression of the neurodegenerative disease, the studys authors reported December 3 at the Clinical Trials on Alzheimers Disease conference in San Diego

Medical history screening is essential

A Next-Generation Medication with Dual Hormone Action Tirzepatide mimics two natural hormones: GLP-1 regulates appetite, slows digestion, stabilizes blood sugar GIP enhances insulin sensitivity, optimizes energy utilization, supports fullness This dual action produces stronger improvements in metabolic health and body weight compared to GLP-1-only medications for many patients